Newsfeeds Archive - Spark Newswire

2 minute read

Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?

June 3, 1:55 PM

Arrowhead Pharmaceuticals announced Phase 3 PALISADE study results showing significant triglyceride reduction in familial chylomicronemia syndrome patients treated with plozasiran.

ARWR

2 minute read

Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday

By Avi Kapoor

June 3, 10:39 AM

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday. Shares of Stericycle,…

ADSK

1 minute read

News

Arrowhead’s Plozasiran Shows Reductions in Triglycerides and Cholesterol in Phase 2 Study

By Benzinga Newsdesk

May 28, 6:06 AM

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia Business Wire - Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3,

ARWR

5 minute read

Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday’s Mid-Day Session

By Avi Kapoor

May 10, 12:44 PM

Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday’s session after the company reported worse-than-expected quarterly financial results.…

ACIC

1 minute read

Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment

By Erica Kollmann

May 2, 5:44 PM

Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses driven by the Horizon acquisition, partially offset by higher revenues.

AMGN

2 minute read

Arrowhead Pharmaceuticals Earns $50M Milestone From Royalty Pharma, Pursuant To Its 2016 Agreement With Amgen And 2022 Agreement With Royalty Pharma, Arrowhead Is Further Eligible To Receive Up To An Additional $375M From Amgen And $110M From Royalty P…

By Benzinga Newsdesk

May 2, 4:39 PM

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ:RPRX). This milestone was triggered after the completion of enrollment of the

AMGN